These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 18416992)

  • 1. A much-anticipated FDA reform bill is signed into law: progress and compromise.
    Nissen SE
    Curr Cardiol Rep; 2008 Feb; 10(1):1-2. PubMed ID: 18416992
    [No Abstract]   [Full Text] [Related]  

  • 2. FDA targets unapproved drugs.
    Young D
    Am J Health Syst Pharm; 2007 Feb; 64(4):347-8. PubMed ID: 17299170
    [No Abstract]   [Full Text] [Related]  

  • 3. Reform bill to speed drugs to residents.
    Hawryluk M
    Provider; 1997 Nov; 23(11):37-8. PubMed ID: 10173669
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmaceuticals and medical devices: FDA oversight. End-of-year issue brief.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2010 Jan; ():1-31. PubMed ID: 20217914
    [No Abstract]   [Full Text] [Related]  

  • 5. US lawmakers tackle safety reforms at the FDA.
    Zwillich T
    Lancet; 2007 Jun; 369(9578):1989-90. PubMed ID: 17577942
    [No Abstract]   [Full Text] [Related]  

  • 6. Good law from tragic facts--Congress, the FDA, and preemption.
    Annas GJ
    N Engl J Med; 2009 Sep; 361(12):1206-11. PubMed ID: 19759383
    [No Abstract]   [Full Text] [Related]  

  • 7. Impact of new regulations for pediatric labeling by the Food and Drug Administration.
    Buck ML
    Pediatr Nurs; 2000; 26(1):95-6. PubMed ID: 12026326
    [No Abstract]   [Full Text] [Related]  

  • 8. Off-label drug use.
    Dooley AG
    Med Health R I; 2007 Feb; 90(2):63-5. PubMed ID: 17500258
    [No Abstract]   [Full Text] [Related]  

  • 9. Coming closer to FDA reform.
    Cimmons M
    Nat Med; 1997 Sep; 3(9):940. PubMed ID: 9288707
    [No Abstract]   [Full Text] [Related]  

  • 10. Off-label prescribing. Legal implications.
    Henry V
    J Leg Med; 1999 Sep; 20(3):365-83. PubMed ID: 10530051
    [No Abstract]   [Full Text] [Related]  

  • 11. FDA Modernization Act: implications for oncology.
    Morris L
    Oncology (Williston Park); 1998 Nov; 12(11A):139-41. PubMed ID: 10028506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tort claims and federal regulation of medical devices vs pharmaceuticals.
    Green M
    JAMA; 2009 Sep; 302(11):1169; author reply 1169-70. PubMed ID: 19755694
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmaceutical provisions of the FDA Modernization Act of 1997: one year and counting.
    Binder GM
    Curr Opin Biotechnol; 1999 Jun; 10(3):303-6. PubMed ID: 10361077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Supplemental applications proposing labeling changes for approved drugs, biologics, and medical devices. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Aug; 73(164):49603-10. PubMed ID: 18958946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Dietary Supplement Health And Education Act: are we healthier and better informed after 27 years?
    Sissung TM; Cordes LM; Figg WD
    Lancet Oncol; 2021 Jul; 22(7):915-916. PubMed ID: 34197743
    [No Abstract]   [Full Text] [Related]  

  • 16. Pros and cons of off-label promotion investigations and prosecutions.
    Loucks MK
    Food Drug Law J; 2006; 61(3):577-83. PubMed ID: 16989041
    [No Abstract]   [Full Text] [Related]  

  • 17. Ejecting the FDA from the courtroom.
    Lancet; 2004 Aug 21-27; 364(9435):638. PubMed ID: 15325808
    [No Abstract]   [Full Text] [Related]  

  • 18. The FDA and deference lost: a self-inflicted wound or the product of a wounded agency? A response to Professor O'Reilly.
    Vladeck DC
    Cornell Law Rev; 2008 Jul; 93(5):981-1002. PubMed ID: 18618967
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmaceuticals and medical devices: FDA oversight.
    Berry MD
    Issue Brief Health Policy Track Serv; 2013 Dec; ():1-123. PubMed ID: 24482893
    [No Abstract]   [Full Text] [Related]  

  • 20. FDA perspectives on supplement use by patients on antithrombotic therapy.
    Kim MJ
    Thromb Res; 2005; 117(1-2):197-200; discussion 201-7. PubMed ID: 16188297
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.